dBET6 / 1 MG

DBET6 is a chemical compound known for its role as a potent and selective degrader of BRD4, a protein involved in gene regulation. It is utilized in biomedical research and drug discovery efforts targeting BRD4-dependent diseases such as cancer and inflammation.

Application:

DBET6 is applied in cellular and molecular biology research to study the function of BRD4 and its implications in disease pathways. It is also used in drug discovery programs aiming to develop targeted therapies for BRD4-associated disorders.

Articles:

- The BET PROTAC inhibitor dBET6 protects against retinal degeneration and inhibits the cGAS-STING in response to light damage

Publication Date: 22 May 2023

Xingfei Zhu, Wei Liu, Xiangcheng Tang, Yulin Chen, Xiangyu Ge, Qin Ke, Xingmiao Liang, Yuwen Gan, Yingfeng Zheng, Ming Zou, Mi Deng, Yizhi Liu, David Wan-Cheng Li & Lili Gong

https://doi.org/10.1186/s12974-023-02804-y

- BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia

Publication Date: 06 July 2022

Barbara Peter, Gregor Eisenwort, Irina Sadovnik, Karin Bauer, Michael Willmann, Thomas Rülicke, Daniela Berger, Gabriele Stefanzl, Georg Greiner, Gregor Hoermann, Alexandra Keller, Dominik Wolf, Martin Čulen, Georg E. Winter, Thomas Hoffmann, Ana-Iris Schiefer, Wolfgang R. Sperr, Johannes Zuber, Jiří Mayer, Peter Valent

https://doi.org/10.1002/ajh.26650

- Cell-type-specific tumour sensitivity identified with a bromodomain targeting PROTAC in adenoid cystic carcinoma

Publication Date: 04 October 2023

Alexandra J Rose, Mercedes M Fleming, Jeffrey C Francis, Jian Ning, Anton Patrikeev, Ritika Chauhan, Kevin J Harrington, Amanda Swain

https://doi.org/10.1002/path.6209